The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric's expansive and growing intellectual property estate CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the…
Read More
Paper co-authored by Enveric researchers describes the discovery of a key cane toad enzyme and its application to the biosynthesis of novel indolethylamine-type drug candidates with potential use in psychiatric…
Read More
Claims to novel composition of matter and pharmaceutical drug formulations encompass EVM301 Series of drug candidates, targeting various difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations CAMBRIDGE, Mass.…
Read More
Poster details advances in screening for non-hallucinogenic, neuroplastogen drug candidates for the treatment of mental health disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
Enveric utilizing AI-backed 3D modeling to identify potential non-hallucinogenic, neuroplastic tryptamine derivative NCEs for its EVM301 Series CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
New patent provides additional composition of matter and methods of use claims for Enveric's tryptamine-derived prodrugs including EB-373, a new chemical entity psilocin prodrug CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and…
Read More
Composition of matter and methods of use claims encompass EB-373, Enveric's new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
Composition of matter and methods of use claims encompass EB-373, Enveric's new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
High purity of manufactured prodrug product allows Enveric and partners to ship EB-373 without being subject to restrictions required for controlled substances CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric"…
Read More
